A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
Condition: Metastatic Breast Cancer Interventions: Drug: Trastuzumab deruxtecan; Drug: Durvalumab; Drug: Paclitaxel; Drug: Capivasertib; Drug: Anastrozole; Drug: Fulvestrant; Drug: Capecitabine Sponsors: AstraZeneca; Daiichi Sankyo Company, Limited Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Arimidex | AstraZeneca | Breast Cancer | Cancer | Cancer & Oncology | HER2 | Research | Study | Xeloda